Table 2.

Adverse events

Grade, n%	CPB (n = 124)	CPA (n = 122)	HR (95%)	p-value
≥ 2 genitourinary fistula	0 (0)	0 (0)	NA	1.000
≥ 2 gastrointestinal fistula	0 (0)	0 (0)	NA	1.000
≥ 3 gastrointestinal bleeding	0 (0)	0 (0)	NA	1.000
≥ 2 hypertension	31 (25.0)	5 (4.1)	7.00 (4.52–6.02)	< 0.001*
≥ 4 neutropenia	42 (33.9)	18 (14.8)	4.00 (3.83–5.36)	< 0.001*
≥ 3 thrombosis/embolism	11 (8.9)	3 (2.5)	2.00 (1.48–3.71)	0.030*
≥ 2 pain	38 (30.6)	34 (27.9)	3.00 (0.14–4.23)	0.633

*Statistically significant. CPB cisplatin-paclitaxel chemotherapy plus bevacizumab, CPA cisplatin-paclitaxel chemotherapy alone, HR Hazard ratio, NA not applicable